



Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

April 20, 2021

CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louise Perry, Head of Technical Operations, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 10:30 am ET.

A live webcast of the fireside chat will be available on the Company's investor relations website, under the Events page accessible here: <https://investors.solidbio.com/news-and-events/events>. A replay will be available on the Company's website following the event.

About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:

David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:

Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com



Source: Solid Biosciences Inc.